文献速递胸部肿瘤

HER2突变NSCLC中T-DXd耐药机制及对后续HER2 TKI敏感性的影响

Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs.
PubMed 文献 · J Thorac Oncol · 2026-01-16

本研究利用临床前耐药模型、LentiMutate扫描诱变和临床分析,探讨HER2突变NSCLC对T-DXd的获得性耐药机制及其对HER2 TKI交叉敏感性的影响。发现耐药可通过载荷耐药(SFLN11缺失、ABCC1/MRP1拷贝数增加)或HER2结构域IV继发突变介导,这些细胞维持HER2信号并对zongertinib或poziotinib保持敏感。既往T-DXd治疗不影响poziotinib的缓解率,HER2缺失并非普遍耐药机制。

要点

  • T-DXd获得性耐药机制包括载荷耐药和HER2结构域IV突变,不必然导致HER2丢失。
  • 载荷耐药或结构域IV突变细胞对HER2 TKI(zongertinib、poziotinib)保持敏感。
  • 既往T-DXd治疗不影响HER2突变NSCLC患者对poziotinib的缓解率。

核心结论

  • HER2突变NSCLC中HER2丢失并非T-DXd耐药的普遍机制。
  • 多种T-DXd耐药机制不导致HER2 TKI敏感性丧失。

研究设计与样本

  • 研究采用T-DXd获得性耐药的临床前模型、LentiMutate扫描诱变和临床分析。

主要发现

  • T-DXd获得性耐药可通过载荷耐药介导,涉及SFLN11缺失和ABCC1/MRP1拷贝数增加。
  • T-DXd耐药也可由HER2结构域IV(曲妥珠单抗结合位点)继发突变介导。
  • 载荷耐药或结构域IV突变的肿瘤细胞维持HER2信号,并对zongertinib或poziotinib保持敏感。
  • 既往接受过T-DXd的HER2突变NSCLC患者接受poziotinib治疗时缓解率相似。

关键数值与推荐

  • HER2突变NSCLC患者无论既往是否接受T-DXd,poziotinib缓解率相似。

临床怎么用

  • T-DXd进展后的HER2突变NSCLC患者可考虑HER2 TKI(如zongertinib或poziotinib)治疗。
  • 耐药机制评估(载荷耐药、HER2结构域IV突变)有助于指导后续HER2靶向治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Effective therapies are needed for patients with NSCLC with HER2-mutant tumors who progress on the HER2 antibody-drug conjugate trastuzumab deruxtecan (T-DXd), a standard-of-care treatment. A greater understanding of mechanisms mediating acquired T-DXd resistance and whether these tumors could benefit from HER2 tyrosine kinase inhibitors (TKIs) is needed. METHODS: Using preclinical models of acquired T-DXd resistance, LentiMutate scanning mutagenesis, and clinical analyses, we investigated mechanisms mediating acquired resistance to T-DXd and assessed the impact of each of these resistance mechanisms on cross-resistance to alternative HER2-targeting approaches. RESULTS: We determined that acquired resistance to T-DXd could occur through multiple mechanisms including payload resistance which could be mediated by SFLN11 loss and copy number gains in the efflux pump ABCC1/MRP1. Moreover, T-DXd resistance could be mediated by secondary HER2 extracellular mutations in domain IV, the trastuzumab binding site. Tumor cells with acquired payload resistance or domain IV mutations maintained HER2 signaling and remained sensitive to HER2 TKIs, including zongertinib or poziotinib. Likewise, patients with HER2-mutant NSCLC treated with poziotinib demonstrated similar response rates regardless of prior T-DXd. CONCLUSIONS: In patients with HER2-mutant NSCLC, loss of HER2 is not a universal mechanism of T-DXd resistance. Collectively, these data highlight multiple mechanisms of resistance to T-DXd that do not result in loss of HER2 TKI responsiveness.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Nilsson MB, Le X, Poteete A, et al. Loss of Payload Sensitivity and Other Mechanisms of Resistance to T-DXd in HER2-Mutant NSCLC: Implications for Subsequent Responsiveness to HER2 TKIs. J Thorac Oncol. 2026. PMID: 41548807. doi:10.1016/j.jtho.2026.01.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。